Antagonism of Paf-induced oedema formation in rabbit skin: a comparison of different antagonists
- 1 May 1989
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 97 (1) , 171-180
- https://doi.org/10.1111/j.1476-5381.1989.tb11939.x
Abstract
Eight platelet activating factor (Paf) antagonists were evaluated as inhibitors of oedema formation in rabbit skin induced by intradermal injection of Paf plus prostaglandin E2 (PGE2). Antagonists were tested by both intradermal (i.d.) and intravenous (i.v.) routes. Intradermal injection of two antagonists structurally-related to Paf (SRI 63-675 and CV-3988) resulted in a partial inhibition of Paf-induced oedema formation but at high doses of antagonist, marked agonist activities were detected. CV-3988 administered i.v. inhibited Paf-induced plasma leakage by 73-80%; however, oedema responses to a range of other inflammatory mediators were also reduced, albeit to a lesser extent (40-60%). SRI 63-675 administered i.v. did not significantly inhibit Paf-induced oedema. The antagonist 48740 RP administered either i.d. showed partial, but selective, inhibition of Paf-induced oedema formation, although the doses required were high when compared with other antagonists. BN 52021 was a weak Paf antagonist when injected i.d., but following i.v. administration the responses to Paf were inhibited by 63-71%. Responses to all other mediators tested were unaffected. Kadsurenone and its synthetic derivatives, L-652,731 and L-659,989 all blocked responses to Paf in the skin. L-659,989 was the most potent, achieving almost total inhibition when injected i.d. and i.v.; moreover, it was selective for Paf. L-652,731 was more potent than kadsurenone. WEB 2086 given i.d. and i.v. showed similar activity to L-659,989 and it was also selective for Paf-induced oedema formation. These results illustrate that in rabbit skin not all Paf antagonists are selective for Paf, some showing agonist-like activity which can mask antagonist properties. It is suggested that before ascribing a role for endogenous Paf in an inflammatory reaction based on results with antagonists, the activity of the antagonists in the model under investigation should be rigorously established.This publication has 24 references indexed in Scilit:
- (±)- Trans -2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonistBiochemical and Biophysical Research Communications, 1988
- Platelet-Activating Factor AntagonistsAnnual Review of Pharmacology and Toxicology, 1987
- EFFECT OF A GINKGOLIDE MIXTURE (BN 52063) IN ANTAGONISING SKIN AND PLATELET RESPONSES TO PLATELET ACTIVATING FACTOR IN MANThe Lancet, 1987
- PAF antagonists: different effects on platelets, neutrophils, guinea pig ileum and PAF-induced vasolidation in isolated rat lungProstaglandins, 1986
- PAF-acether specific binding sites: 2. Design of specific antagonistsTrends in Pharmacological Sciences, 1986
- INVOLVEMENT OF PLATELET ACTIVATING FACTOR IN RESPIRATORY ANAPHYLAXIS, DEMONSTRATED BY PAF-ACETHER INHIBITOR BN 52021The Lancet, 1985
- Synergism between platelet-activating factor (PAF-acether) and prostaglandin E2 in manEuropean Journal of Pharmacology, 1984
- Detection of the complement fragment C5a in inflammatory exudates from the rabbit peritoneal cavity using radioimmunoassay.The Journal of Experimental Medicine, 1983
- CV-3988 - A specific antagonist of platelet activating factor (PAF)Life Sciences, 1983
- Control of vascular permeability by polymorphonuclear leukocytes in inflammationNature, 1981